Loading…
Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects
Background: Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context. Objective: With this work we want...
Saved in:
Published in: | Journal of Alzheimer's disease 2024-01, Vol.98 (3), p.1029-1042 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c344t-ea8661e783f38f77d56c11c08bf2e18329b9dc52c5263003523eff47de5510eb3 |
container_end_page | 1042 |
container_issue | 3 |
container_start_page | 1029 |
container_title | Journal of Alzheimer's disease |
container_volume | 98 |
creator | Martínez-Dubarbie, Francisco López-García, Sara Lage, Carmen Di Molfetta, Guglielmo Fernández-Matarrubia, Marta Pozueta-Cantudo, Ana García-Martínez, María Corrales-Pardo, Andrea Bravo, María Jiménez-Bonilla, Julio Quirce, Remedios Marco de Lucas, Enrique Drake-Pérez, Marta Tordesillas, Diana López-Hoyos, Marcos Irure-Ventura, Juan Valeriano-Lorenzo, Elizabeth Blennow, Kaj Ashton, Nicholas J. Zetterberg, Henrik Rodríguez-Rodríguez, Eloy Sánchez-Juan, Pascual |
description | Background:
Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context.
Objective:
With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters.
Methods:
We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits. We performed a Linear Mixed-effects Model to analyze their rate of change. We also correlated their baseline levels with cognitive tests and structural and functional image values. ATN status was defined based on cerebrospinal fluid biomarkers.
Results:
Plasma p-tau231 showed a significant rate of change over time. It correlated negatively with memory tests only in amyloid-positive subjects. No significant correlations were found with any imaging measures.
Conclusions:
Increases in plasma p-tau231 can be detected at one-year intervals in cognitively healthy subjects. It could constitute a sensitive marker for detecting early signs of neuronal network impairment by amyloid. |
doi_str_mv | 10.3233/JAD-231479 |
format | article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_gup_ub_gu_se_338905</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3233_JAD-231479</sage_id><sourcerecordid>2958298336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-ea8661e783f38f77d56c11c08bf2e18329b9dc52c5263003523eff47de5510eb3</originalsourceid><addsrcrecordid>eNptkVtr3DAQhUVpaC7tS39AEfShoeBW0tiW9Bi2t4RAAk0e-qTK9njjxbdKVsr--0zZbQolIBgxfJyZM4ex11J8AAXw8eLsU6ZA5to-Y0fS6CIzVpjn9AejM2W0PmTHMW6EECCsfsEOweTGSiuP2M_r3sfB8-u7Kc53U9j2fsGG3_jESZKfj3VAHzFyv_CrEbMf6AN1Fwz3vo-8G_lqWo_d0t1jv-W3YzfMvguk8D1VG6yX-JIdtETiq309YbdfPt-svmWXV1_PV2eXWQ15vmToTVlK1AZaMK3WTVHWUtbCVK1CaUDZyjZ1oeiVQD4KBdi2uW6wKKTACk5YttONv3FOlZtDN_iwdZPv3DrNjlrr5CI6ALpOQfzpjp_D9CthXNzQxRr73o84peiULYyyBqAk9O1_6GZKYSQ3DuiiWhtrNVHvd1QdphgDto8rSOH-5OQoJ7fLieA3e8lUDdg8on-DIeDd3o5f4795T0g9AN5VmGU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3030778997</pqid></control><display><type>article</type><title>Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Martínez-Dubarbie, Francisco ; López-García, Sara ; Lage, Carmen ; Di Molfetta, Guglielmo ; Fernández-Matarrubia, Marta ; Pozueta-Cantudo, Ana ; García-Martínez, María ; Corrales-Pardo, Andrea ; Bravo, María ; Jiménez-Bonilla, Julio ; Quirce, Remedios ; Marco de Lucas, Enrique ; Drake-Pérez, Marta ; Tordesillas, Diana ; López-Hoyos, Marcos ; Irure-Ventura, Juan ; Valeriano-Lorenzo, Elizabeth ; Blennow, Kaj ; Ashton, Nicholas J. ; Zetterberg, Henrik ; Rodríguez-Rodríguez, Eloy ; Sánchez-Juan, Pascual</creator><creatorcontrib>Martínez-Dubarbie, Francisco ; López-García, Sara ; Lage, Carmen ; Di Molfetta, Guglielmo ; Fernández-Matarrubia, Marta ; Pozueta-Cantudo, Ana ; García-Martínez, María ; Corrales-Pardo, Andrea ; Bravo, María ; Jiménez-Bonilla, Julio ; Quirce, Remedios ; Marco de Lucas, Enrique ; Drake-Pérez, Marta ; Tordesillas, Diana ; López-Hoyos, Marcos ; Irure-Ventura, Juan ; Valeriano-Lorenzo, Elizabeth ; Blennow, Kaj ; Ashton, Nicholas J. ; Zetterberg, Henrik ; Rodríguez-Rodríguez, Eloy ; Sánchez-Juan, Pascual</creatorcontrib><description>Background:
Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context.
Objective:
With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters.
Methods:
We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits. We performed a Linear Mixed-effects Model to analyze their rate of change. We also correlated their baseline levels with cognitive tests and structural and functional image values. ATN status was defined based on cerebrospinal fluid biomarkers.
Results:
Plasma p-tau231 showed a significant rate of change over time. It correlated negatively with memory tests only in amyloid-positive subjects. No significant correlations were found with any imaging measures.
Conclusions:
Increases in plasma p-tau231 can be detected at one-year intervals in cognitively healthy subjects. It could constitute a sensitive marker for detecting early signs of neuronal network impairment by amyloid.</description><identifier>ISSN: 1387-2877</identifier><identifier>ISSN: 1875-8908</identifier><identifier>EISSN: 1875-8908</identifier><identifier>DOI: 10.3233/JAD-231479</identifier><identifier>PMID: 38489191</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Alzheimer's disease ; Biomarkers ; Cerebrospinal fluid ; Cognitive ability ; Correlation ; Intervals ; longitudinal study ; Neural networks ; Neurodegenerative diseases ; Neurosciences ; Neurovetenskaper ; p-tau231 ; Plasma ; plasma biomarkers ; Plasma levels ; presymptomatic stages ; Structure-function relationships ; Tau protein</subject><ispartof>Journal of Alzheimer's disease, 2024-01, Vol.98 (3), p.1029-1042</ispartof><rights>2024 – IOS Press. All rights reserved</rights><rights>Copyright IOS Press BV 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c344t-ea8661e783f38f77d56c11c08bf2e18329b9dc52c5263003523eff47de5510eb3</cites><orcidid>0000-0002-1482-7813</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38489191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/338905$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez-Dubarbie, Francisco</creatorcontrib><creatorcontrib>López-García, Sara</creatorcontrib><creatorcontrib>Lage, Carmen</creatorcontrib><creatorcontrib>Di Molfetta, Guglielmo</creatorcontrib><creatorcontrib>Fernández-Matarrubia, Marta</creatorcontrib><creatorcontrib>Pozueta-Cantudo, Ana</creatorcontrib><creatorcontrib>García-Martínez, María</creatorcontrib><creatorcontrib>Corrales-Pardo, Andrea</creatorcontrib><creatorcontrib>Bravo, María</creatorcontrib><creatorcontrib>Jiménez-Bonilla, Julio</creatorcontrib><creatorcontrib>Quirce, Remedios</creatorcontrib><creatorcontrib>Marco de Lucas, Enrique</creatorcontrib><creatorcontrib>Drake-Pérez, Marta</creatorcontrib><creatorcontrib>Tordesillas, Diana</creatorcontrib><creatorcontrib>López-Hoyos, Marcos</creatorcontrib><creatorcontrib>Irure-Ventura, Juan</creatorcontrib><creatorcontrib>Valeriano-Lorenzo, Elizabeth</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Ashton, Nicholas J.</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Rodríguez-Rodríguez, Eloy</creatorcontrib><creatorcontrib>Sánchez-Juan, Pascual</creatorcontrib><title>Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects</title><title>Journal of Alzheimer's disease</title><addtitle>J Alzheimers Dis</addtitle><description>Background:
Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context.
Objective:
With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters.
Methods:
We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits. We performed a Linear Mixed-effects Model to analyze their rate of change. We also correlated their baseline levels with cognitive tests and structural and functional image values. ATN status was defined based on cerebrospinal fluid biomarkers.
Results:
Plasma p-tau231 showed a significant rate of change over time. It correlated negatively with memory tests only in amyloid-positive subjects. No significant correlations were found with any imaging measures.
Conclusions:
Increases in plasma p-tau231 can be detected at one-year intervals in cognitively healthy subjects. It could constitute a sensitive marker for detecting early signs of neuronal network impairment by amyloid.</description><subject>Alzheimer's disease</subject><subject>Biomarkers</subject><subject>Cerebrospinal fluid</subject><subject>Cognitive ability</subject><subject>Correlation</subject><subject>Intervals</subject><subject>longitudinal study</subject><subject>Neural networks</subject><subject>Neurodegenerative diseases</subject><subject>Neurosciences</subject><subject>Neurovetenskaper</subject><subject>p-tau231</subject><subject>Plasma</subject><subject>plasma biomarkers</subject><subject>Plasma levels</subject><subject>presymptomatic stages</subject><subject>Structure-function relationships</subject><subject>Tau protein</subject><issn>1387-2877</issn><issn>1875-8908</issn><issn>1875-8908</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptkVtr3DAQhUVpaC7tS39AEfShoeBW0tiW9Bi2t4RAAk0e-qTK9njjxbdKVsr--0zZbQolIBgxfJyZM4ex11J8AAXw8eLsU6ZA5to-Y0fS6CIzVpjn9AejM2W0PmTHMW6EECCsfsEOweTGSiuP2M_r3sfB8-u7Kc53U9j2fsGG3_jESZKfj3VAHzFyv_CrEbMf6AN1Fwz3vo-8G_lqWo_d0t1jv-W3YzfMvguk8D1VG6yX-JIdtETiq309YbdfPt-svmWXV1_PV2eXWQ15vmToTVlK1AZaMK3WTVHWUtbCVK1CaUDZyjZ1oeiVQD4KBdi2uW6wKKTACk5YttONv3FOlZtDN_iwdZPv3DrNjlrr5CI6ALpOQfzpjp_D9CthXNzQxRr73o84peiULYyyBqAk9O1_6GZKYSQ3DuiiWhtrNVHvd1QdphgDto8rSOH-5OQoJ7fLieA3e8lUDdg8on-DIeDd3o5f4795T0g9AN5VmGU</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Martínez-Dubarbie, Francisco</creator><creator>López-García, Sara</creator><creator>Lage, Carmen</creator><creator>Di Molfetta, Guglielmo</creator><creator>Fernández-Matarrubia, Marta</creator><creator>Pozueta-Cantudo, Ana</creator><creator>García-Martínez, María</creator><creator>Corrales-Pardo, Andrea</creator><creator>Bravo, María</creator><creator>Jiménez-Bonilla, Julio</creator><creator>Quirce, Remedios</creator><creator>Marco de Lucas, Enrique</creator><creator>Drake-Pérez, Marta</creator><creator>Tordesillas, Diana</creator><creator>López-Hoyos, Marcos</creator><creator>Irure-Ventura, Juan</creator><creator>Valeriano-Lorenzo, Elizabeth</creator><creator>Blennow, Kaj</creator><creator>Ashton, Nicholas J.</creator><creator>Zetterberg, Henrik</creator><creator>Rodríguez-Rodríguez, Eloy</creator><creator>Sánchez-Juan, Pascual</creator><general>SAGE Publications</general><general>IOS Press BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope><orcidid>https://orcid.org/0000-0002-1482-7813</orcidid></search><sort><creationdate>20240101</creationdate><title>Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects</title><author>Martínez-Dubarbie, Francisco ; López-García, Sara ; Lage, Carmen ; Di Molfetta, Guglielmo ; Fernández-Matarrubia, Marta ; Pozueta-Cantudo, Ana ; García-Martínez, María ; Corrales-Pardo, Andrea ; Bravo, María ; Jiménez-Bonilla, Julio ; Quirce, Remedios ; Marco de Lucas, Enrique ; Drake-Pérez, Marta ; Tordesillas, Diana ; López-Hoyos, Marcos ; Irure-Ventura, Juan ; Valeriano-Lorenzo, Elizabeth ; Blennow, Kaj ; Ashton, Nicholas J. ; Zetterberg, Henrik ; Rodríguez-Rodríguez, Eloy ; Sánchez-Juan, Pascual</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-ea8661e783f38f77d56c11c08bf2e18329b9dc52c5263003523eff47de5510eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer's disease</topic><topic>Biomarkers</topic><topic>Cerebrospinal fluid</topic><topic>Cognitive ability</topic><topic>Correlation</topic><topic>Intervals</topic><topic>longitudinal study</topic><topic>Neural networks</topic><topic>Neurodegenerative diseases</topic><topic>Neurosciences</topic><topic>Neurovetenskaper</topic><topic>p-tau231</topic><topic>Plasma</topic><topic>plasma biomarkers</topic><topic>Plasma levels</topic><topic>presymptomatic stages</topic><topic>Structure-function relationships</topic><topic>Tau protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez-Dubarbie, Francisco</creatorcontrib><creatorcontrib>López-García, Sara</creatorcontrib><creatorcontrib>Lage, Carmen</creatorcontrib><creatorcontrib>Di Molfetta, Guglielmo</creatorcontrib><creatorcontrib>Fernández-Matarrubia, Marta</creatorcontrib><creatorcontrib>Pozueta-Cantudo, Ana</creatorcontrib><creatorcontrib>García-Martínez, María</creatorcontrib><creatorcontrib>Corrales-Pardo, Andrea</creatorcontrib><creatorcontrib>Bravo, María</creatorcontrib><creatorcontrib>Jiménez-Bonilla, Julio</creatorcontrib><creatorcontrib>Quirce, Remedios</creatorcontrib><creatorcontrib>Marco de Lucas, Enrique</creatorcontrib><creatorcontrib>Drake-Pérez, Marta</creatorcontrib><creatorcontrib>Tordesillas, Diana</creatorcontrib><creatorcontrib>López-Hoyos, Marcos</creatorcontrib><creatorcontrib>Irure-Ventura, Juan</creatorcontrib><creatorcontrib>Valeriano-Lorenzo, Elizabeth</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Ashton, Nicholas J.</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Rodríguez-Rodríguez, Eloy</creatorcontrib><creatorcontrib>Sánchez-Juan, Pascual</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Journal of Alzheimer's disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez-Dubarbie, Francisco</au><au>López-García, Sara</au><au>Lage, Carmen</au><au>Di Molfetta, Guglielmo</au><au>Fernández-Matarrubia, Marta</au><au>Pozueta-Cantudo, Ana</au><au>García-Martínez, María</au><au>Corrales-Pardo, Andrea</au><au>Bravo, María</au><au>Jiménez-Bonilla, Julio</au><au>Quirce, Remedios</au><au>Marco de Lucas, Enrique</au><au>Drake-Pérez, Marta</au><au>Tordesillas, Diana</au><au>López-Hoyos, Marcos</au><au>Irure-Ventura, Juan</au><au>Valeriano-Lorenzo, Elizabeth</au><au>Blennow, Kaj</au><au>Ashton, Nicholas J.</au><au>Zetterberg, Henrik</au><au>Rodríguez-Rodríguez, Eloy</au><au>Sánchez-Juan, Pascual</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects</atitle><jtitle>Journal of Alzheimer's disease</jtitle><addtitle>J Alzheimers Dis</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>98</volume><issue>3</issue><spage>1029</spage><epage>1042</epage><pages>1029-1042</pages><issn>1387-2877</issn><issn>1875-8908</issn><eissn>1875-8908</eissn><abstract>Background:
Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context.
Objective:
With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters.
Methods:
We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits. We performed a Linear Mixed-effects Model to analyze their rate of change. We also correlated their baseline levels with cognitive tests and structural and functional image values. ATN status was defined based on cerebrospinal fluid biomarkers.
Results:
Plasma p-tau231 showed a significant rate of change over time. It correlated negatively with memory tests only in amyloid-positive subjects. No significant correlations were found with any imaging measures.
Conclusions:
Increases in plasma p-tau231 can be detected at one-year intervals in cognitively healthy subjects. It could constitute a sensitive marker for detecting early signs of neuronal network impairment by amyloid.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>38489191</pmid><doi>10.3233/JAD-231479</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-1482-7813</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1387-2877 |
ispartof | Journal of Alzheimer's disease, 2024-01, Vol.98 (3), p.1029-1042 |
issn | 1387-2877 1875-8908 1875-8908 |
language | eng |
recordid | cdi_swepub_primary_oai_gup_ub_gu_se_338905 |
source | SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list) |
subjects | Alzheimer's disease Biomarkers Cerebrospinal fluid Cognitive ability Correlation Intervals longitudinal study Neural networks Neurodegenerative diseases Neurosciences Neurovetenskaper p-tau231 Plasma plasma biomarkers Plasma levels presymptomatic stages Structure-function relationships Tau protein |
title | Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Phosphorylated%20Tau%20231%20Increases%20at%20One-Year%20Intervals%20in%20Cognitively%20Unimpaired%20Subjects&rft.jtitle=Journal%20of%20Alzheimer's%20disease&rft.au=Mart%C3%ADnez-Dubarbie,%20Francisco&rft.date=2024-01-01&rft.volume=98&rft.issue=3&rft.spage=1029&rft.epage=1042&rft.pages=1029-1042&rft.issn=1387-2877&rft.eissn=1875-8908&rft_id=info:doi/10.3233/JAD-231479&rft_dat=%3Cproquest_swepu%3E2958298336%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c344t-ea8661e783f38f77d56c11c08bf2e18329b9dc52c5263003523eff47de5510eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3030778997&rft_id=info:pmid/38489191&rft_sage_id=10.3233_JAD-231479&rfr_iscdi=true |